Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept
Anshuman P Malaviya,1 Andrew JK Östör1,2
1Rheumatology Clinical Research Unit, Addenbrooke's Hospital, Cambridge, UK; 2School of Clinical Medicine, University of Cambridge, Cambridge, UK
Abstract: Major advances in drug development have led to the introduction of biologic disease-modifying drugs for the treatment of rheumatoid arthritis, which has resulted in unprecedented improvement in outcomes for many patients. These agents have been found to be effective in reducing clinical signs and symptoms, improving radiological damage, quality of life, and functionality, and have also been found to have an acceptable safety profile. Despite this, drug adherence is unknown, which has huge health care and health-economic implications. Local and national guidelines exist for the use of biologics; however, its varied use is widespread. Although this may in part reflect differences in prescribing behavior, patient preference plays a key role. In this review we will explore the factors that contribute to patient preference for, and adherence to, biologic therapy for rheumatoid arthritis with emphasis on the subcutaneous preparation of abatacept, a T-cell costimulatory molecule blocker. Overall, subcutaneous administration is preferred by patients and this may well improve drug adherence.
Keywords: subcutaneous administration, self-injectable, abatacept, rheumatoid arthritis, preference, adherence, compliance, biologic DMARD
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.